Author: ddAdmin
A proud moment for Jubilant Biosys !!
CDD Vault to support Jubilant networked research to advance the collaborative experience with their customers.
Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years. Jubilant will be using CDD Vault as their informatics platform to facilitate and boost transparent distribution of research data and information. CDD Vault manages biological assay data, involved chemical structures, reactions and compound properties in a cohesive environment.
“CDD Vault will be used across Jubilant research sites; to keep experimental information centralized, both structured and unstructured, to share with clients.” said Marcel Velterop, President of Drug Discovery Services & CDMO at Jubilant Biosys Limited. “Scientists will be able to explore their chemistry and biology data in real-time, enabling rapid decision-making of discovery programs with CDD Vault”.
“Jubilant is a leading collaborator for pharmaceutical and biotechnology companies worldwide and we are delighted to assist them in sharing their high quality preclinical R&D services with the life science industry” said Dr. Mariana Vaschetto, General Manager, CDD Global Business. “CDD Vault has been designed for collaborative research within or between organizations in a secure and easy to use way. We are looking forward to this long term relationship with Jubilant and helping them ensure the success of their customers’ research.”
About Collaborative Drug Discovery
CDD’s (www.collaborativedrug.com) flagship product, “CDD Vault®”, is used to manage chemical registration, structure activity relationships (SAR) and securely scale collaborations. CDD Vault®, a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data and collaborate with internal or external partners through an easy to use web interface. Available modules include Activity & Registration, Visualization, Inventory and ELN.
About Jubilant Biosys Limited
Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd., is an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise across multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. Business models include both functional and integrated discovery services up to IND including GLP as well as Phase 1/2 GMP supplies, as core components which are available for collaborative research.
Leveraging the Orbitrap HRMS for met-ID & large molecule analysis
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
Authors: Sven Ruf, Sridharan Rajagopal, Sanjay Venkatachalapathi Kadnur, Mahanandeesha S. Hallur, Shilpa Rani, Rajendra Kristam, Srinivasan Swaminathan, Bharat Ravindra Zope, Pavan Kumar Gondrala, Indu Swamy, V. P. Rama Kishore Putta, Saravanan Kandan, Gernot Zech, Herman Schreuder, Christine Rudolph, Ralf Elvert, Joerg Czech, Swarnakumari Birudukota, M. Amir Siddiqui, Niranjan Naranapura Anand, Vishal Subhash Mane, Sreekanth Dittakavi, Juluri Suresh, Ramachandraiah Gosu, Mullangi Ramesh, Takeshi Yura, Saravanakumar Dhakshinamoorthy & Aimo Kannt
Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics.
Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.
ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score
Authors: K.V. Sanjay, Santosh Vishwakarma, Bharat Ravindra Zope, Vishal Subhash Mane, Sunil Mohire, Saravanakumar Dhakshinamoorthy
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
Novel Inhibitors of Nicotinamide-N-Methyltransferase for the Treatment of Metabolic Disorders
Authors: Aimo Kannt, Sridharan Rajagopal, Mahanandeesha S. Hallur, Indu Swamy, Rajendra Kristam, Saravanakumar Dhakshinamoorthy, Joerg Czech, Gernot Zech, Herman Schreuder and Sven Ruf
Jubilant Biosys and Yale University announce collaboration
New Haven, CT. & Bengaluru, India—Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.